Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.38 |
| ▸ | CNR2 | P34972 | 9/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | CNR1 | P21554 | 7/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14232096 | 0.88 | HPGD (0.42) | HPGDMAPTSMN1; SMN2TAAR1CNR2 | |
| SCHEMBL19617998 | 0.84 | HPGD (0.56) | HPGDMAPTSMN1; SMN2TAAR1CNR2 | |
| SCHEMBL10030729 | 0.84 | HPGD (0.56) | HPGDMAPTSMN1; SMN2TAAR1CNR2 | |
| SCHEMBL15478179 | 0.79 | HPGD (0.50) | HPGDSMN1; SMN2TAAR1CNR2MEN1 | |
| SCHEMBL14232233 | 0.77 | SIRT2 (0.42) | HPGDMEN1KMT2A | |
| SCHEMBL838460 | 0.77 | MAPT (0.50) | MAPTSMN1; SMN2CNR2CNR1 | |
| SCHEMBL10030734 | 0.76 | THRB (0.50) | HPGDMAPTSMN1; SMN2TAAR1CNR2 | |
| SCHEMBL21141379 | 0.76 | HDAC1 (0.44) | CNR2 | |
| SCHEMBL16746640 | 0.76 | EPHX2 (0.47) | MAPTCNR2MEN1KMT2ACNR1 | |
| SCHEMBL13182760 | 0.76 | MAPT (0.47) | MAPTSMN1; SMN2CNR2CNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9006478-B2 | Diurethane gelators for curable ink applications | XEROX CORPORATION (US) | 2015-04-14 | — | — | US | disclosed |
| US-20140213816-A1 | DIURETHANE GELATORS FOR CURABLE INK APPLICATIONS | XEROX CORPORATION (US) | 2014-07-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140213816-A1 | DIURETHANE GELATORS FOR CURABLE INK APPLICATIONS | CCNA2, CCNA1, CCNT1 | HPGD 853/4885MAPT 4490/4885SMN1; SMN2 2290/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.